Sequenom's Q4 Revenues More than Double; Shares Fall in Early Trade | GenomeWeb

NEW YORK (GenomeWeb News) – Sequenom reported after the close of the market Thursday that its fourth-quarter revenues more than doubled year over year, as the firm edged out the Wall Street estimate on the top line.

Despite the strong revenue growth, Sequenom's shares fell in early Friday trade as the firm missed estimates on the bottom line and gave limited information on test volume and reimbursement expectations for its flagship prenatal test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.